The effects of chemotherapy agents used to treat paediatric acute lymphoblastic leukaemia on bone parameters and longitudinal growth of juvenile mice

Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer. Therapies for paediatric ALL have improved such that more than 80% of patients survive to 5 years post-therapy, and most survive to adulthood. However, these ALL patients experience long-term side effects, which permanently affect their quality of life. Bone loss is the most common skeletal abnormality in paediatric ALL survivors, and 40% of patients experience a fracture before therapy completion. Reduced longitudinal growth (short stature) is another significant side effect of ALL therapy.
Source: Experimental Hematology - Category: Hematology Authors: Tags: 3129 Source Type: research